Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin

Yusuf, 2001, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345, 494, 10.1056/NEJMoa010746

Steinhubl, 2002, Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial, JAMA, 288, 2411, 10.1001/jama.288.19.2411

Barragan, 2003, Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation, Catheter Cardiovasc Interv, 59, 295, 10.1002/ccd.10497

Lau, 2003, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction, Circulation, 107, 32, 10.1161/01.CIR.0000047060.60595.CC

Fontana, 2003, Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects, Circulation, 108, 989, 10.1161/01.CIR.0000085073.69189.88

Hulot, 2006, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 2244, 10.1182/blood-2006-04-013052

Ishizaki, 1999, Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole, Aliment Pharmacol Ther, 13, 27, 10.1046/j.1365-2036.1999.00022.x

Gilard, 2006, Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin, J Thromb Haemost, 4, 2508, 10.1111/j.1538-7836.2006.02162.x

Schwarz, 1999, Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets—definition and detection of ticlopidine/clopidogrel effects, Thromb Haemost, 82, 1145, 10.1055/s-0037-1614344

Matetzky, 2004, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction, Circulation, 109, 3171, 10.1161/01.CIR.0000130846.46168.03

Lau, 2004, Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance, Circulation, 109, 166, 10.1161/01.CIR.0000112378.09325.F9

Clarke, 2003, The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin, Drug Metab Dispos, 31, 53, 10.1124/dmd.31.1.53

Saw, 2003, Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial, Circulation, 108, 921, 10.1161/01.CIR.0000088780.57432.43

Serebruany, 2004, Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study, Arch Intern Med, 164, 2051, 10.1001/archinte.164.18.2051

Gurbel, 2003, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83

Geiger, 2005, Monitoring of clopidogrel action: comparison of methods, Clin Chem, 51, 957, 10.1373/clinchem.2004.047050

Aleil, 2005, Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases, J Thromb Haemost, 3, 85, 10.1111/j.1538-7836.2004.01063.x

Jaremo, 2002, Individual variations of platelet inhibition after loading doses of clopidogrel, J Intern Med, 252, 233, 10.1046/j.1365-2796.2002.01027.x

Richter, 2004, Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine, J Pharmacol Exp Ther, 308, 189, 10.1124/jpet.103.056127

Schwab, 2004, CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori, Clin Pharmacol Ther, 76, 201, 10.1016/j.clpt.2004.05.002